K. made) was performed if visible. For all the patients, bed rest activity, semi-sitting position, and eye shield protection were recommended. The patients were treated with tranexamic acid (5%) eye drop [one ampoule tranexamic acid (500 mg/5ml) (TRANEXIP), Caspian Tamin Pharmaceutical Co., in 5 ml of artificial tear eye drop (TEARLOSE) containing

hydroxypropyl methyl, cellulose, and dextran (Sina Daru Pharmaceutical Co.)] for 5 days every 6 hours. If corneal epithelium abrasion was observed, chloramphenicol eye drop was added every 6 hours. If IOP was Inhibitors,research,lifescience,medical >22 mm Hg, one or two topical anti-glaucoma medications were added. The main outcome kinase inhibitor Belinostat measures were BCVA, IOP, day of clot absorption, and rate of rebleeding. These parameters were kinase inhibitor MG132 evaluated daily for 4 days and thereafter at the 8th and 14th days after the treatment began. The BCVA and IOP values were compared with these parameters before the treatment. In each follow-up Inhibitors,research,lifescience,medical visit, the patients were asked about subjective changes or side effects

and they were checked for any objective ocular or systemic side effect of tranexamic acid. The patients in the present study were compared (chi-squared test and t test) with two historical control groups of patients with traumatic hyphema who Inhibitors,research,lifescience,medical had previously been treated; one group with oral placebo and the other one with oral tranexamic acid at our department.10 Both studies were done after our institutional Ethics Committee had approved the study protocol and informed consent had been obtained from all the participants (Ethics Committee’s code number: 89-01-19-2016). All Inhibitors,research,lifescience,medical the statistical analyses were performed using Statistical

Package for Social Sciences software, version 16 (SPSS Inc., Chicago, IL, USA). A P<0.05 was considered statistically significant. Results Thirty eyes of 30 patients at a mean age of 27.4±10.6 years old, ranging from 8 to 48, were included in this study. Twenty four (80%) patients were male and 6 (20%) were female. Eighteen (60%) eyes were right eyes and 12 (40%) were left eyes. Twenty-two (73.3%) Inhibitors,research,lifescience,medical patients had grade 1, 5 (16.7%) had grade 2, and 3 (10%) had grade 3 layer hyphema. No patient had grade 4 hyphema. The mean logarithm of the minimum angle of resolution (logMAR) BCVA before treatment was 0.59±0.62, with a range of 0.00 to 3.00, which changed to 0.08±0.14, ranging from 0.00 to 0.70, on day Carfilzomib 14 (P<0.001). The mean IOP before treatment was 13.7±3.9 mm Hg, ranging from 8 to 28 mm Hg, which decreased to 11.4±1.8 mm Hg, ranging from 9 to 16 mm Hg on day 14 (P=0.004). The mean day of clot absorption was 4.1±1.7 days. Rebleeding occurred only in one (3.3%) patient on day 4. This patient had grade 2 layer hyphema initially and topical tranexamic acid was started 8 hours after trauma. Because of rebleeding, conventional treatment (oral tranexamic acid) was started and final logMAR BCVA was 0.1 and IOP was 12 mm Hg.